Arrowhead Research
ARWR
$88.70
+2.38%
Arrowhead Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics for diseases with genetic origins or protein overexpression, targeting areas such as cardiometabolic, neuromuscular, pulmonary, and liver diseases. As a pioneer in RNAi medicine, Arrowhead distinguishes itself through its proprietary targeted delivery platforms and a robust pipeline of clinical candidates. The current investor narrative centers on the company's transformative year, marked by a 361% surge in stock price over the past year, driven by promising clinical data, strategic partnerships, and growing optimism about its lead candidates' commercial potential. Recent attention has also been fueled by positive momentum in the broader gene therapy space, as evidenced by CRISPR Therapeutics' commercial updates, which bodes well for RNAi-based approaches.…
ARWR
Arrowhead Research
$88.70
Related headlines
Investment Opinion: Should I buy ARWR Today?
Based on the analysis, ARWR is rated a 'Buy' with a strong conviction, supported by a 'Strong Buy' consensus from 11 analysts and an average target price of $110.18, implying 27.2% upside. The core thesis is that Arrowhead's innovative RNAi platform and pipeline have significant commercial potential, and the recent stock surge reflects growing confidence in its ability to deliver on that potential.
Sign up to view all
ARWR 12-Month Price Forecast
The AI assessment is bullish, driven by strong analyst conviction and the company's innovative platform. However, confidence is medium due to the extreme revenue volatility and high valuation. The key factor is whether Arrowhead can convert its pipeline into stable revenue streams. If the company delivers positive clinical data and secures new partnerships, the stock could reach the high target. Conversely, any setbacks could lead to a sharp correction. The stance would be upgraded to high confidence if revenue stabilizes and the company approaches profitability, but downgraded if clinical failures occur.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Arrowhead Research's 12-month outlook, with a consensus price target around $110.18 and implied upside of +24.2% versus the current price.
Average Target
$110.18
0 analysts
Implied Upside
+24.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$100 - $126
Analyst target range
The target price range spans from a low of $100.00 to a high of $126.00, representing a spread of 26% from low to high, which indicates moderate uncertainty about the stock's future performance. The high target of $126.00 implies a 45.4% upside from the current price and likely assumes successful clinical trial results, regulatory approvals, and significant commercial uptake of lead candidates. The low target of $100.00 still implies a 15.4% upside, suggesting that even the most bearish analysts see value in the stock, but they may be pricing in potential delays or competitive pressures. The relatively tight range and the strong buy consensus signal high conviction among analysts, though the wide spread between the low and high targets highlights the binary nature of biotech investing, where clinical outcomes can dramatically alter the stock's trajectory.
Bulls vs Bears: ARWR Investment Factors
Arrowhead presents a compelling growth story with a 361% stock surge, strong analyst support, and a promising RNAi platform. However, the company's financials are marked by extreme revenue volatility, persistent losses, and a high valuation that leaves little margin for error. The bull case rests on successful pipeline advancement and new partnerships, while the bear case centers on the inability to generate stable revenue and the risk of a valuation correction. Currently, the bull side has stronger evidence given the strong analyst conviction and recent positive momentum, but the single most important tension is whether Arrowhead can convert its clinical promise into consistent commercial revenue, which would justify its premium valuation.
Bullish
- Explosive 1-Year Stock Performance: ARWR surged 361.3% over the past year, vastly outperforming the S&P 500's +20.4%. This reflects strong investor conviction in the company's RNAi platform and pipeline, with the stock trading near its 52-week high of $95.49.
- Strong Analyst Conviction with High Targets: Analysts rate ARWR a 'Strong Buy' with an average target of $110.18, implying 27.2% upside from the current $86.64. The low target of $100 still offers 15.4% upside, indicating even the most bearish analyst sees value.
- Robust Pipeline and Strategic Partnerships: Arrowhead's RNAi platform targets multiple therapeutic areas (cardiometabolic, neuromuscular, pulmonary, liver). Recent momentum in gene therapy, as seen with CRISPR's Casgevy adoption, bodes well for RNAi approaches, potentially driving future partnership deals.
- Healthy Balance Sheet with High Liquidity: Current ratio of 4.86 indicates strong short-term liquidity, and debt-to-equity of 0.79 is manageable for a biotech. This financial stability supports continued R&D investment without immediate dilution risk.
Bearish
- Extreme Revenue Volatility: Quarterly revenue swung from $542.7M in Q2 FY2025 to $73.7M in Q2 FY2026, an 86.4% YoY decline. This lumpiness, driven by milestone timing, makes financial forecasting difficult and raises concerns about revenue sustainability.
- Persistent Net Losses and Negative EPS: The most recent quarter posted a net loss of $132.7M and EPS of -$0.93. Trailing P/E is negative (-2827x), and forward P/E is also negative (-17.8x), indicating continued losses are expected, which could pressure the stock if losses widen.
- High Valuation with No Earnings Support: P/S ratio of 5.56x and EV/Sales of 17.73x are elevated for a company with declining revenue. The PEG ratio of 28.34x suggests the stock is priced for perfection, leaving little room for disappointment.
- Extended Stock Price Near Highs: Trading at 90.8% of its 52-week range, the stock is overextended. The recent 1-month gain of 20.6% and a max drawdown of -24.6% indicate high volatility and potential for a sharp pullback if sentiment shifts.
ARWR Technical Analysis
Arrowhead's stock is in a powerful sustained uptrend, with a 1-year price change of +361.3%, dramatically outperforming the S&P 500's +20.4% over the same period. The current price of $86.64 sits at 90.8% of its 52-week range (low of $18.725, high of $95.49), indicating the stock is trading near its highs, reflecting strong momentum but also potential overextension. This positioning suggests bullish sentiment is dominant, though investors should be cautious of a possible pullback given the extended nature of the rally.
Beta
1.29
1.29x market volatility
Max Drawdown
-24.6%
Largest decline past year
52-Week Range
$19-$95
Price range past year
Annual Return
+332.5%
Cumulative gain past year
| Period | ARWR Return | S&P 500 |
|---|---|---|
| 1m | +19.4% | +4.0% |
| 3m | +21.2% | +5.3% |
| 6m | +37.8% | +12.6% |
| 1y | +332.5% | +20.1% |
| ytd | +30.8% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ARWR Fundamental Analysis
Arrowhead's revenue trajectory has been highly volatile, with the most recent quarter (Q2 FY2026, ended March 31, 2026) reporting revenue of $73.7 million, a dramatic 86.4% decline year-over-year from the $542.7 million reported in the same quarter last year. This decline follows a pattern of lumpy revenue recognition, as the company's revenue is heavily dependent on milestone payments and partnership agreements. For instance, Q1 FY2026 (December 2025) saw revenue of $264.0 million, while Q4 FY2025 (September 2025) had $256.5 million, but Q3 FY2025 (June 2025) was only $27.8 million. The multi-quarter trend shows significant fluctuations, with growth accelerating in some quarters and contracting sharply in others, reflecting the unpredictable nature of collaboration income. The investment case hinges on the company's ability to secure new partnerships and advance its pipeline to generate more stable, recurring revenue streams.
Quarterly Revenue
$73737000.0B
2026-03
Revenue YoY Growth
-86.4%
YoY Comparison
Gross Margin
100.0%
Latest Quarter
Free Cash Flow
$-50872000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ARWR Overvalued?
Given that Arrowhead reported a net loss of $132.7 million in the most recent quarter, the trailing P/E ratio is negative (-2827.0), making it meaningless for valuation. Therefore, I have selected the price-to-sales (P/S) ratio as the primary valuation metric, which stands at 5.56x on a trailing basis. The forward P/E ratio is also negative (-17.8), indicating that analysts expect continued losses in the near term. The gap between the negative trailing and forward earnings multiples suggests the market is pricing in a return to profitability further out, likely driven by anticipated milestone payments and potential product approvals.
PE
-2827.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 1x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
28.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant, as Arrowhead's revenue is highly volatile, swinging from $542.7M in Q2 FY2025 to $73.7M in Q2 FY2026, an 86.4% decline. The company reported a net loss of $132.7M in the latest quarter, with negative EPS of -$0.93, and trailing P/E is negative (-2827x). While the current ratio of 4.86 indicates strong liquidity, the reliance on milestone payments creates cash flow unpredictability, and the negative free cash flow of -$50.9M TTM suggests ongoing cash burn. The debt-to-equity ratio of 0.79 is moderate, but if revenue fails to materialize, the company may need to raise capital, diluting shareholders.